Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Allogene intends to utilize Arbor's CRISPR technology with its own proprietary platform to develop next-generation allogeneic CAR T (AlloCAR T) therapies targeting autoimmune diseases (AID). However, neither of the companies disclosed any specific financial terms or considerations pertaining to the above transaction. Management intends to start a clinical study on its first AlloCAR T therapy in AID indication in early 2025. This is in line with the company's previous announcement of starting an early-stage clinical study on a new candidate ALLO-329 in lupus/systemic lupus erythematosus indication next year. Shares of Allogene have jumped 52.7% in the year-to-date period compared with the industry's 1.1% growth. Image Source: Zacks Investment Research Earlier at the onset of this year, management made major changes to its pipeline when it announced its business plans for 2024 and beyond. As part of its business update, ALLO announced that it is deprioritizing two pivotal m
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell CarcinomaGlobeNewswire
- Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]Yahoo! Finance
- CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Announces Q2 Investor Conference ParticipationGlobeNewswire
ALLO
Earnings
- 3/14/24 - Miss
ALLO
Sec Filings
- 4/26/24 - Form EFFECT
- 4/24/24 - Form 4
- 4/23/24 - Form ARS
- ALLO's page on the SEC website